Association of fibrinogen gene polymorphism with Q–T interval indicators in patients with arterial hypertension and type 2 diabetes mellitus

• Vafa B. Nazirova

Abstract

Aim. To study the distribution of polymorphic variants of the fibrinogen gene FGB and the association of genotypes with Q–T interval indicators in people with arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) in Azerbaijan.

Material and methods. The study included 76 patients and 24 people in the control group. Aged 32 to 77. The patients were divided into 3 groups: 1^st group consisted of 29 patients with AH, 2^nd group consisted of 23 patients with AH and coronary heart disease (CHD), 3^rd group consisted of 24 patients with AH, CHD and T2DM. Patients underwent an ECG and measurement of blood pressure (SBP/DBP – systolic blood pressure/diastolic blood pressure). Determination of the fibrinogen gene FGB G (-455) A polymorphism was carried out by mass spectrometry (MALDI-TOF).

Results. The occurrence of the fibrinogen gene FGB G (-455) A polymorphism in all groups revealed the predominance of the homozygous genotype G/G. In our studies, patients with T2DM (3 group) showed a predominance of heterozygous genotype G/A.

Conclusion. Predominance of the G allele and a statistically significant occurrence of the homozygous genotype G/G of the fibrinogen gene FGB G (-455) A was observed in patients of Azerbaijani nationality. Moreover, patients with AH + СHD + T2DM have a statistically significant difference in the frequency of occurrence of the fibrinogen gene FGB G (-455) A G/A polymorphism, compared to the group of patients without T2DM.

Keywords:arterial hypertension; type 2 diabetes mellitus; fibrinogen gene FGB; polymorphism; Azerbaijani nationality

References

1. Ametov A.S., P’yanykh O.P., Depyui T.I. Management of cardiorenal risks in patients with type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (2): 105–11. DOI: https://doi.org/10.33029/2304-9529-2021-10-2-105-11 (in Russian)

2. Mekhdiev S.K., Mustafaev I.I., Mamedov M.N. Features of glycemic status and risk factors in patients with coronary artery disease and type 2 diabetes in Azerbaijan population. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2019; (6): 85–91. DOI: https://doi.org/10.15829/1560-4071-2019-6-85-91 (in Russian)

3. Malinova L.I., Furman N.V., Dolotovskaya P.V., Puchin’yan N.F., Kiselev A.R. Platelet indices as markers of platelet turnover and aggregation: pathophysiological interpretation, clinical impact, perspectives in research (review). Saratovskiy nauchno-meditsinskiy zhurnal [Saratov Journal of Medical Scientific Research]. 2017; 13 (4): 813–20. (in Russian)

4. Eswaran A., Kunnath A.P., Hon G.M., Ayob Y.A.B., Tharmajan P. Relationship between platelet indices and coronary heart disease in Malaysian population. J Biomed Sci. 2020; 9 (3): 1–6.

5. Li D., Zhang X., Huang H., Zhang H. Association of β-fibrinogen polymorphisms and venous thromboembolism risk: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019; 98 (48): e18204. DOI: https://doi.org/10.1097/MD.0000000000018204

6. Yang S.H., Du Y., Zhang Y., Li X.L., Li S., Xu R.X., et al. Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study. BMJ. 2017; 7 (6): e015041. DOI: https://doi.org/10.1136/bmjopen-2016-015041

7. Surma S., Maciej B. Fibrinogen and atherosclerotic cardiovascular diseases – review of the literature and clinical studies. Int J Mol Sci. 2022; 23 (1): 193. DOI: https://doi.org/10.3390/ijms23010193

8. Veljkovic N., Zaric B., Djuric I., Obradovic M., Sudar-Milovanovic E., Radak D., et al. Genetic markers for coronary artery disease. Medicina (Kaunas). 2018; 54 (3): 36. DOI: https://doi.org/10.3390/medicina54030036

9. Simurda T., Brunclikova M., Asselta R., Caccia S., Zolkova J., Kolkova Z., et al. Genetic variants in the FGB and FGG genes mapping in the beta and gamma nodules of the fibrinogen molecule in congenital quantitative fibrinogen disorders associated with a thrombotic phenotype. Int J Mol Sci. 2020; 21: 4616. DOI: https://doi.org/10.3390/ijms21134616

10. Al H.A., Bawady S.A., Saab A.A., El Kilany W., Allam A.S., Metwally S.S. Clinical significance of platelet antigen 1/platelet antigen 2 (PlA1/A2) polymorphism of integrin β 3 (ITGB 3) gene in coronary artery disease. Med J Cairo Univ. 2019; 87 (6): 3969–75.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)